Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 21
Newsletter articlesFull Text
"Anti-Cxcr4 Antibody Combined With Activated And Expanded Natural Killer Cells For Cancer Immunotherapy" in Patent Application Approval Process (USPTO 20230181635)
Publisher:NewsRX LLC
Journal title:Vaccine Weekly, 2023, p.59
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 22
Newsletter articlesFull Text
Patent Issued for Treatment Of iC1013G/CXCR4/I-Associated Waldenstrom'S Macroglobulinemia With An anti-CXCR4 Antibody (USPTO 11220548)
Publisher:NewsRX LLC
Journal title:Hematology Week, 2022, p.1015
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 23
ArticlesPeer ReviewedFull Text
233. Using Recombinant SV40 Vectors To Deliver Antioxidant and Anti-CXCR4 Transgenes To Prevent Neuronal Apoptosis
Publisher:Elsevier Inc
Journal title:Molecular therapy, 2003-05, Vol.7 (5), p.S92-S92
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 24
ArticlesFull Text
Jinan University Researchers Further Understanding of Cancer (Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity)
Publisher:NewsRX LLC
Journal title:Obesity, fitness, & wellness week, 2021-01, p.2547
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 25
Newsletter articlesFull Text
State Intellectual Property Office of China Releases Institute Biophysics, CAS's Patent Application for Anti-CXCR4 Single-Domain Antibody, Bispecific Antibody and Drug Conjugate
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 26
Newsletter articlesFull Text
MSM Protein Technologies Submits Patent Application for Anti-CXCR4 Antibodies
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2019
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 27
Newsletter articlesFull Text
Pfizer (PFE) issued patent titled "Anti-CXCR4 antibodies and antibody-drug conjugates"
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites - Pharmaceuticals & Biotechnology, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 28
Newsletter articlesFull Text
Dana-Farber Cancer Institute, Bristol-Myers Squibb Assigned Patent for Treatment of C1013G/CXCR4-Associated Waldenstrom's Macroglobulinemia with Anti-CXCR4 Antibody
Publisher:Washington, D.C: Targeted News Service
Journal title:Targeted News Service, 2022
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 29
Newsletter articlesFull Text
Bristol-Myers Squibb Secures Patent on Treatment of C1013G/CXCR4-Associated Waldenstrom's Macroglobulinemia with an Anti-CXCR4 Antibody
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2022
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 30
ArticlesFull Text
Researchers at Moores Cancer Center Report Findings in Chronic Lymphocytic Leukemia [Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leu...
Publisher:NewsRX LLC
Journal title:Obesity, fitness, & wellness week, 2016-07, p.3746
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 31
Newsletter articlesFull Text
Bristol-Myers Squibb Applies for Patent on Treatment of Hematologic Malignancies with an Anti-CXCR4 Antibody
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2020
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 32
Newsletter articlesFull Text
Recent Studies from Anqing Municipal Hospital Add New Data to Multiple Myeloma (Doxorubicin-loaded PEG-CdTe QDs conjugated with anti-CXCR4 mAbs: a novel delivery system for extramedullary multiple mye...
Publisher:NewsRX LLC
Journal title:Hematology Week, 2024, p.3845
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 33
Newsletter articlesFull Text
US Patent Issued to PFIZER on Feb. 23 for "Anti-CXCR4 antibodies and antibody-drug conjugates" (California Inventors)
Publisher:Washington, D.C: HT Digital Streams Limited
Journal title:US Fed News Service, Including US State News, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 34
Newsletter articlesFull Text
Pfizer Inc Files Patent Application for Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Publisher:New Delhi: Athena Information Solutions Pvt. Ltd
Journal title:Indian Patents News, 2020
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 35
Newsletter articlesFull Text
Bristol Myers Squibb (BMY) issued patent titled "Treatment of hematologic malignancies with an anti-CXCR4 antibody"
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites - Pharmaceuticals & Biotechnology, 2019
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 36
Newsletter articlesFull Text
Pfizer (PFE) issued patent titled "Anti-CXCR4 antibodies and antibody-drug conjugates"
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites - Pharmaceuticals & Biotechnology, 2019
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 37
ArticlesFull Text
Recent Findings from National Center for Scientific Research (CNRS) Has Provided New Data on Multiple Myeloma (Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone...
Publisher:NewsRX LLC
Journal title:Obesity, fitness, & wellness week, 2018-06, p.4419
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 38
Newsletter articlesFull Text
U.S. Patent and Trademark Office Receives Pfizer Inc's Patent Application for Anti-Cxcr4 Antibodies and Antibody-Drug Conjugates
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2020
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 39
Newsletter articlesFull Text
Pfizer Inc Files United States Patent Application for Anti-CXCR4 Antibodies and Antibody-Drug Conjugates
Publisher:New Delhi: Pedia Content Solutions Pvt. Ltd
Journal title:Global IP News. Pharmaceutical Patent News, 2019
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 40
Newsletter articlesFull Text
US Patent Issued to Bristol-Myers Squibb, DANA-FARBER CANCER INSTITUTE on Jan. 11 for "Treatment of C1013G/CXCR4 -associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody" (Massachusetts...
Publisher:Washington, D.C: HT Digital Streams Limited
Journal title:US Fed News Service, Including US State News, 2022
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 21 to 40 of 192 results

Export record to excel

Export this record

Export record to excel

"Anti-Cxcr4 Antibody Combined With Activated And Expanded Natural Killer Cells For Cancer Immunotherapy" in Patent Application Approval Process (USPTO 20230181635)

Export this record

Export record to excel

Patent Issued for Treatment Of iC1013G/CXCR4/I-Associated Waldenstrom'S Macroglobulinemia With An anti-CXCR4 Antibody (USPTO 11220548)

Export this record

Export record to excel

233. Using Recombinant SV40 Vectors To Deliver Antioxidant and Anti-CXCR4 Transgenes To Prevent Neuronal Apoptosis

Export this record

Export record to excel

Jinan University Researchers Further Understanding of Cancer (Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity)

Export this record

Export record to excel

State Intellectual Property Office of China Releases Institute Biophysics, CAS's Patent Application for Anti-CXCR4 Single-Domain Antibody, Bispecific Antibody and Drug Conjugate

Export this record

Export record to excel

MSM Protein Technologies Submits Patent Application for Anti-CXCR4 Antibodies

Export this record

Export record to excel

Pfizer (PFE) issued patent titled "Anti-CXCR4 antibodies and antibody-drug conjugates"

Export this record

Export record to excel

Dana-Farber Cancer Institute, Bristol-Myers Squibb Assigned Patent for Treatment of C1013G/CXCR4-Associated Waldenstrom's Macroglobulinemia with Anti-CXCR4 Antibody

Export this record

Export record to excel

Bristol-Myers Squibb Secures Patent on Treatment of C1013G/CXCR4-Associated Waldenstrom's Macroglobulinemia with an Anti-CXCR4 Antibody

Export this record

Export record to excel

Researchers at Moores Cancer Center Report Findings in Chronic Lymphocytic Leukemia [Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leu...

Export this record

Export record to excel

Bristol-Myers Squibb Applies for Patent on Treatment of Hematologic Malignancies with an Anti-CXCR4 Antibody

Export this record

Export record to excel

Recent Studies from Anqing Municipal Hospital Add New Data to Multiple Myeloma (Doxorubicin-loaded PEG-CdTe QDs conjugated with anti-CXCR4 mAbs: a novel delivery system for extramedullary multiple mye...

Export this record

Export record to excel

US Patent Issued to PFIZER on Feb. 23 for "Anti-CXCR4 antibodies and antibody-drug conjugates" (California Inventors)

Export this record

Export record to excel

Pfizer Inc Files Patent Application for Anti-CXCR4 Antibodies and Antibody-Drug Conjugates

Export this record

Export record to excel

Bristol Myers Squibb (BMY) issued patent titled "Treatment of hematologic malignancies with an anti-CXCR4 antibody"

Export this record

Export record to excel

Pfizer (PFE) issued patent titled "Anti-CXCR4 antibodies and antibody-drug conjugates"

Export this record

Export record to excel

Recent Findings from National Center for Scientific Research (CNRS) Has Provided New Data on Multiple Myeloma (Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone...

Export this record

Export record to excel

U.S. Patent and Trademark Office Receives Pfizer Inc's Patent Application for Anti-Cxcr4 Antibodies and Antibody-Drug Conjugates

Export this record

Export record to excel

Pfizer Inc Files United States Patent Application for Anti-CXCR4 Antibodies and Antibody-Drug Conjugates

Export this record

Export record to excel

US Patent Issued to Bristol-Myers Squibb, DANA-FARBER CANCER INSTITUTE on Jan. 11 for "Treatment of C1013G/CXCR4 -associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody" (Massachusetts...

Refine your search